Clinical Trials Logo

Clinical Trial Summary

The Peroxisome Biogenesis Disorders (PBD) are a group of inherited disorders due to defects in peroxisome assembly causing complex developmental and metabolic sequelae. In spite of advancements in peroxisome biology, the pathophysiology remains unknown, the spectrum of phenotypes poorly characterized and the natural history not yet systematically reported. Our aims are to further define this population clinically, biochemically and genetically. The investigators will prospectively follow patients from Canada, the US and internationally, and collect data from medical evaluations, blood, urine and imaging studies that would be performed on a clinical care basis. For patients who are unable to attend our clinic, we will collect all medical records and images since birth as well as subsequent records/images for the next 5 years or until the end of the study. Clinical data from medical records will be banked in our Peroxisomal Disorder Research Databank and Biobank. The investigators will use this information to identify standards of care and improve management.


Clinical Trial Description

Participants have the option to be seen in consultation at the McGill University Health Centre in Montreal, Canada, on a yearly basis. This includes a consultation in Genetics, Nutrition, Neurology, and Ophthalmology (OCT and FAF exams). All medical records and images will be collected, retrospectively and prospectively, until the end of the study, and entered anonymously in a database. Biospecimens will be collected to identify new biomarkers. Candidate drugs will be evaluated for recovery of peroxisome functions in cultured fibroblasts. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01668186
Study type Observational
Source McGill University Health Centre/Research Institute of the McGill University Health Centre
Contact Nancy E Braverman, MD, MS
Phone (1) 514-934-1934
Email nancy.braverman@mcgill.ca
Status Recruiting
Phase
Start date January 2012
Completion date January 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04569162 - Rhizomelic Chondrodysplasia Punctata Registry